Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis

Leptomeningeal metastasis (LM) is a lethal complication in patients with non-small cell lung cancer (NSCLC) that leads to a poor prognosis [1,2]. The incidence of LM has been increasing, accounting for 3 –5 % in molecularly unselected NSCLC patients and up to 9–16 % in epidermal growth factor receptor (EGFR)-mutant lung cancer patients [2–4]. This increased incidence may be attributed to the prolonged survival of patients with EGFR-mutated NSCLC owing to the introduction of EGFR-tyrosine k inase inhibitors (TKIs).

Source: Lung Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Haicheng Wu, Qian Zhang, Wanchen zhai, Yunfei Chen, Yehao Yang, Mingning Xie, Zhiyu Huang, Yanjun Xu, Hui Li, Lei Gong, Sizhe Yu, Yun Fan, Kaiyan Chen Source Type: research